发明名称 |
Intraperitoneally-administered nanocarriers that release their therapeutic load based on the inflammatory environment of cancers |
摘要 |
In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein. |
申请公布号 |
US9532949(B2) |
申请公布日期 |
2017.01.03 |
申请号 |
US201214233527 |
申请日期 |
2012.07.18 |
申请人 |
STC.UNM |
发明人 |
Zeineldin Reema |
分类号 |
A61K9/51;A61K9/127;A61K31/704;A61K9/00 |
主分类号 |
A61K9/51 |
代理机构 |
Schwegman Lundberg & Woessner, P.A. |
代理人 |
Schwegman Lundberg & Woessner, P.A. |
主权项 |
1. A method of treating a subject who suffers from a cancer, the method comprising intraperitoneally administering to the subject a pharmaceutically effective amount of a nanocarrier composition, comprising a plurality of porous nanoparticulates that are loaded with one or more pharmaceutically active anticancer agents and are encapsulated by and support a lipid bilayer which is disrupted upon contact with a reactive oxygen species, wherein the lipid bilayer comprises 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC). |
地址 |
Albuquerque NM US |